Search in:
The study, promoted and financed by the Catholic University, led by its researchers Juan Carlos Izpisua and José Meca, and with the collaboration of the Hospital Virgen de la Arrixaca, has a clear Murcian stamp.
In this prestigious Times Higher Education report, the UCAM has climbed 478 places compared to last year in the world ranking in research. Moreover, it is the regional leader from an international perspective as well as in transfer of knowledge towards the business world
Through an economic contribution or by disseminating the project it is possible to collaborate to this research, included in the FECYT Precipita platform (Spanish Ministry of Science and Innovation), which aims at developing a screening system through artificial intelligence that would reduce by 85% the pathologist’s workload, thus allowing to implement a population programme of early diagnosis. It is developed by researchers of UCAM Universidad Católica San Antonio de Murcia, the Polytechnic University of Valencia, the CIAGO Gynaecological Clinic of Torre Pacheco and the Santa Lucía and Santa María del Rosell university hospitals of Cartagena.
A team of scientists led by Juan Carlos Izpisúa, director of the Gene Expression Laboratory at Salk Institute in the USA and Extraordinary Professor of Developmental Biology at UCAM, has developed a method, with unprecedented efficiency, that makes it possible to obtain pancreatic β-cells suitable for autotransplantation from human iPS cells.
The results of the study, published today in the Nature Communications journal, represent a major step forward that will benefit athletes and the elderly in particular
The development of this patent has been possible thanks to the study carried out by UCAM and the IMIB to find new drugs that act by reducing the migration and invasion of tumour cells
It holds the first position in the Region and it is included in the top-ten in Spain
The findings on cellular communication hold promise for early human development, disease progression and aging, as well as organ transplantation and for testing therapeutics
It can analyze 96 samples at the same time, identifying Sars-CoV-2 with its variants, influenza viruses, adenoviruses and other human coronaviruses. In only 15 minutes it starts giving results and in three hours it finishes all the samples.
The researchers belong to the Universidad Católica de Murcia, the Murcian Institute of Biosanitary Research and the University of Granada.
